Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2010.

"We have recently passed a number of key milestones in our clinical program, most notably the opening of enrollment in our Phase 3 head and neck cancer study, the expansion of the study to other jurisdictions internationally, and the reporting of positive results from an earlier study with an emphasis on squamous cell carcinoma of the head and neck," said Dr. Brad Thompson, President and CEO of Oncolytics. "While our Phase 3 study remains our primary focus, we have also successfully expanded our clinical program to include other indications as REOLYSIN(R) may be effective in treating a variety of cancers."

    Selected Highlights
    -------------------

Since April 1, 2010 the Company has announced:

Clinical Trial Results

        -  A poster presentation at the American Society of Clinical Oncology
           2010 Annual Meeting, entitled "A Phase I/II study of oncolytic
           reovirus plus carboplatin/paclitaxel in patients with advanced
           solid cancers with emphasis on squamous cell carcinoma of the head
           and neck (SCCHN)," showing that of 19 head and neck cancer
           patients evaluable for response, eight (42%) had partial responses
           and six (32%) had stable disease; mean overall survival in 24
           treated head and neck cancer patients was more than eight months;
        -  Publication of a paper entitl
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 US demand to rise 3.9% annually ... is forecast to rise 3.9 percent per year to ... projected to increase 1.3 percent per year to 1.5 ... in construction expenditures will support demand for biocides in ... growth in consumer spending and manufacturing output will support ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
(Date:9/21/2014)... first time, scientists have discovered how to produce ultra-thin ... stiffness greater than that of today,s strongest nanotubes and ... team led by John V. Badding, a professor of ... the 21 September 2014 issue of the journal ... view, our discovery is intriguing because the threads we ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4
... EXTON, Pa., July 15 Morphotek((R)), Inc., a subsidiary of ... a privately held biotechnology company specializing in the development of ... evaluation and option agreement in which Morphotek will evaluate monoclonal ... , The agreement with CII provides Morphotek ...
... , SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ ... Company"), a leading Chinese firm,specializing in the manufacture, research, ... financial results for,the fourth quarter and fiscal year ended ... Quarter 2009 Highlights, -- Net sales ...
... First Half of 2009 (Excluding Technical, Plastics) ... Business, - Sales Decline in the Cyclical Segments of ... In the first half of 2009, Gerresheimer AG achieved sales ... was,mainly attributable to sales growth for pharmaceutical packaging and systems,with which Gerresheimer ...
Cached Biology Technology:Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 2Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13Gerresheimer Holds its own in Difficult Environment 2Gerresheimer Holds its own in Difficult Environment 3Gerresheimer Holds its own in Difficult Environment 4
(Date:9/22/2014)... CHAMPAIGN, Ill. Antarctic fishes that manufacture their ... Southern Ocean also suffer an unfortunate side effect, ... inside their bodies resist melting even when temperatures ... the Proceedings of the National Academy of ... be an undesirable consequence of the evolution of ...
(Date:9/22/2014)... seven institutions in the country selected by the ... year,s BEST Award a $2 million grant ... promising biomedical sciences graduate trainees to career opportunities ... have traditionally taken. , The award funds development ... Scientists (iJOBs) program. It includes courses, seminars, shadowing, ...
(Date:9/22/2014)... Most of the fires captured in this image burn in ... of Okhotsk. Dozens of red hotspots, accompanied by plumes of ... or grey, blows to the east towards the Sea of ... north of this area, swampy forest inhabit the central depression, ... , While large wildfires are common in Russia in the ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... York, NY (April 18, 2013) An excess of ... psychosis in people who are at risk for schizophrenia, ... Center (CUMC) published in the current issue of ... diagnostic tool for identifying those at risk for schizophrenia ...
... has been presented today to Professor Adolfo Diez-Perez, MD, ... Hospital del Mar, Director of the Bone and Joint ... and Professor of Medicine at the Autonomous University of ... IOF Medal of Achievement every two years to honour ...
... fatty and sugary foods. Or do they? New research contradicts ... have the same taste in food and highlights the importance ... preferences. SINC Until now the scientific ... sugary drinks, the very foods that are the most damaging ...
Cached Biology News:High levels of glutamate in brain may kick-start schizophrenia 2IOF Medal of Achievement awarded to Professor Adolfo Diez-Perez 2Tell me where you're from and I'll tell you what tastes you prefer 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: